Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Pembrolizumab in Advanced Melanoma with HR Mutations
NCT04633902Phase 2Unknown
- Sponsor
- California Pacific Medical Center Research Institute
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in melanoma, sponsored by California Pacific Medical Center Research Institute. Status: unknown.
02
Drugs
olaparib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04633902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633902.